Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application.
Aged
Antimetabolites, Antineoplastic
/ administration & dosage
Dose-Response Relationship, Drug
Drug Combinations
Female
Fluorouracil
/ blood
Humans
Male
Middle Aged
Neoplasms
/ drug therapy
Nomograms
Oxonic Acid
/ administration & dosage
Renal Insufficiency
/ complications
Tegafur
/ administration & dosage
S-1
dosage formula
nomogram
renal function
target AUC of 5-FU
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
11
09
2020
revised:
29
11
2020
accepted:
30
11
2020
pubmed:
6
12
2020
medline:
2
3
2021
entrez:
5
12
2020
Statut:
ppublish
Résumé
In patients with impaired renal function, S-1-related toxicities increase due to higher exposure of 5-fluorouracil (5-FU). Our previous pharmacokinetic study in 16 cancer patients with various renal functions developed an S-1 dosage formula based on individual creatinine clearance (CLcr) and body surface area (BSA). To evaluate and refine the formula, this prospective study was conducted. Thirty-three patients with various renal functions received S-1 for 4 weeks at doses determined by the nomogram derived from the previously developed formula. A series of blood samples were collected after the first dose to calculate the area under the concentration-time curve (AUC) of 5-FU. Thirty patients with BSA of 1.14-1.84 m
Identifiants
pubmed: 33277781
doi: 10.1111/cas.14758
pmc: PMC7894007
doi:
Substances chimiques
Antimetabolites, Antineoplastic
0
Drug Combinations
0
S 1 (combination)
150863-82-4
Tegafur
1548R74NSZ
Oxonic Acid
5VT6420TIG
Fluorouracil
U3P01618RT
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
751-759Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP17K08961
Informations de copyright
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Ann Oncol. 2015 Jul;26(7):1401-8
pubmed: 25908605
Cancer Res. 1996 Jun 1;56(11):2602-6
pubmed: 8653704
J Clin Oncol. 2000 Jul;18(14):2772-9
pubmed: 10894878
Ann Oncol. 2018 Mar 1;29(3):624-631
pubmed: 29293874
N Engl J Med. 2007 Nov 1;357(18):1810-20
pubmed: 17978289
Ann Oncol. 2013 May;24(5):1326-31
pubmed: 23277482
Ann Oncol. 2009 May;20(5):946-9
pubmed: 19150953
J Clin Oncol. 2011 Nov 20;29(33):4387-93
pubmed: 22010012
Cancer Sci. 2021 Feb;112(2):751-759
pubmed: 33277781
J Clin Oncol. 1992 Jul;10(7):1171-5
pubmed: 1607921
Cancer Chemother Pharmacol. 2013 Feb;71(2):361-70
pubmed: 23139054
Clin Cancer Res. 1999 Aug;5(8):2000-5
pubmed: 10473078
J Clin Oncol. 2010 Mar 20;28(9):1547-53
pubmed: 20159816
J Clin Oncol. 1999 Apr;17(4):1105
pubmed: 10561167
Gastric Cancer. 2005;8(1):6-11
pubmed: 15747168
Lancet Oncol. 2016 Jan;17(1):90-8
pubmed: 26617202
Lancet Oncol. 2013 Dec;14(13):1278-86
pubmed: 24225157
Ann Oncol. 2006 Nov;17(11):1656-60
pubmed: 16968871
Cancer Sci. 2019 Jun;110(6):1987-1994
pubmed: 30989775
Anticancer Drugs. 1996 Jul;7(5):548-57
pubmed: 8862723
Clin Chem. 1987 Dec;33(12):2299-300
pubmed: 3484334
Ann Oncol. 2017 Nov 1;28(11):2698-2706
pubmed: 29045553
Nephron. 1976;16(1):31-41
pubmed: 1244564
Gastric Cancer. 2016 Jul;19(3):876-86
pubmed: 26304171
Cancer Chemother Pharmacol. 2002 Jul;50(1):25-32
pubmed: 12111108
Ann Oncol. 2019 Dec 1;30(12):1950-1958
pubmed: 31566666
Lancet. 2016 Jul 16;388(10041):248-57
pubmed: 27265347
Ann Oncol. 2015 Jan;26(1):141-148
pubmed: 25316259
Lancet Oncol. 2008 Mar;9(3):215-21
pubmed: 18282805
J Clin Oncol. 1989 Nov;7(11):1748-56
pubmed: 2681557